Done Deal: Johnson & Johnson Completes Acquisition of Proteologix, Inc.
Johnson & Johnson has completed the acquisition of Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash with potential for an additional milestone payment, as announced on May 16, 2024. Proteologix’s portfolio includes PX128, a bispecific antibody targeting interleukin (IL)-13 plus TSLP, which is ready to […]